Document:

SEC Connect

 

EXHIBIT
10.1

 

FIRST AMENDMENT TO AMENDED AND RESTATED SECURITIES PURCHASE
AGREEMENT

 

THIS
FIRST AMENDMENT TO AMENDED AND RESTATED SECURITIES PURCHASE
AGREEMENT (this “Amendment”), dated as of May ___,
2017, by and among MEDITE Cancer Diagnostics, Inc., a Delaware
corporation, with headquarters located at 4203 SW 34th Street, Orlando,
Florida 32811 (the “Company”), and each buyer
identified on Schedule I of the Purchase Agreement (defined below),
as the same may be updated from time to time in accordance with
this Purchase Agreement (which buyer, including its successors and
assigns, a “Buyer” and collectively, the
“Buyers”).
 Capitalized terms used herein without definition shall have
the meanings assigned to such terms in the Purchase
Agreement. 

 

RECITALS

 

             

WHEREAS, the
Parties have entered into that certain Amended and Restated
Securities Purchase Agreement whereby the Company intends to
conduct a private placement of its common stock, par value $0.001,
at a per share price of $0.50, in accordance with Rule 506 of
Regulation D of the Securities Act of 1933, with a Maximum Offering
Amount of $4,250,000 (as the same may from time to time be amended,
modified, supplemented, or restated, the “Purchase Agreement”);
and

             

 

 

WHEREAS,
in accordance with Section 8(e) of the Purchase Agreement, the
Parties have agreed to amend the Purchase Agreement pursuant to
this Amendment, as set forth herein.

  

AGREEMENT

 

             

In consideration of
the mutual covenants and promises contained herein and for other
good and valuable consideration, the receipt and adequacy of which
are hereby acknowledged, each Party agrees to amend the Purchase
Agreement as follows:

 

1.

Amendment to Authorized
Warrants. The amount of Warrants authorized to be issued
pursuant to the Purchase Agreement is hereby increased from 2,
125,000 to up to 4,661,915.

 

2.

Amendment to Disclosure
Schedule.                                                                            

 

3.

Binding. The provisions of this
Amendment shall be binding on and shall inure to the benefit of the
parties hereto and their respective successors and
assigns.

 

4.

Effectiveness; Effective Date.
Except to the extent specifically set forth herein, all other terms
and provisions of the Purchase Agreement shall remain in full force
and effect without change. This Amendment shall be effective as of
the date first set forth above.

 

5.

Governing Law. This Amendment
shall be governed by and construed in accordance with the laws of
the State of Delaware without regard to the conflict of law
provisions thereof.

 

6.

Counterparts. This
Amendment may be executed in one or more counterparts, each of
which will be deemed to be an original copy of this Amendment and
all of which, when taken together, will be deemed to constitute one
and the same agreement.

 

IN
WITNESS WHEREOF, the parties hereto have caused this First
Amendment to Securities Purchase Agreement to be duly executed by
their respective authorized signatories as of the date first
indicated above.

 

“COMPANY”

 

MEDITE
CANCER DIAGNOSTICS, INC.

 

 

 

By:
______________________________________

   
   David Patterson, Chief Executive Officer

 

“BUYER”

 

 

__________________________________________

 

 

 

 

 

 

EXHIBIT
“A”

 

Disclosure Schedule
3(c)SHARE
PURCHASE AGREEMENT

 

AMONG

 

VBI
VACCINES INC.

 

AND

 

THE
INVESTORS PARTY HERETO

  

    	 	 	 

    	 		 

    

 

TABLE
OF CONTENTS

 

	 	Page
	 	 
	Article
    I DEFINITIONS	 1
	 	 
	1.1
    Definitions	 1
	 	 
	Article
    II PURCHASE AND SALE	5
	 	 
	2.1
    (a) Closing	 5
	2.2
    Pre-Closing and Closing Deliveries; Irrevocable Subscription.	7
	 	 
	Article
    III REPRESENTATIONS AND WARRANTIES	8
	 	 
	3.1
    Representations and Warranties of the Company	8
	3.2
    Representations and Warranties of the Investors	 12
	 	 
	Article
    IV OTHER AGREEMENTS OF THE PARTIES	19
	 	 
	4.1
    Transfer Restrictions.	19
	 	 
	Article
    V CONDITIONS	20
	 	 
	5.1
    Conditions Precedent to the Obligations of the Investors	 20
	5.2
    Conditions Precedent to the Obligations of the Company	21
	 	 
	Article
    VI INDEMNIFICATION	22
	 	 
	6.1
    Indemnification of Investors	 22
	6.2
    Conduct of Indemnification Proceedings	 22
	 	 
	Article
    VII MISCELLANEOUS	23
	 	 
	7.1
    Termination	 23
	7.2
    Fees and Expenses	 23
	7.3
    Entire Agreement; Further Assurances	 23
	7.4
    Notices	 23
	7.5
    Amendments; Waivers	24
	7.6
    Construction	24
	7.7
    Successors and Assigns	24
	7.8
    No Third-Party Beneficiaries	24
	7.9
    Governing Law; Venue; Waiver of Jury Trial	24
	7.10
    Survival	25
	7.11
    Execution	25
	7.12
    Severability	25
	7.13
    Independent Nature of Investors’ Obligations and Rights	 25
	7.14
    Representations	26
	 	 
	EXHIBITS	 
	 	 
	EXHIBIT
    A-1	 
	EXHIBIT
    A-2	 
	EXHIBIT
    A-3	 
	APPENDIX
    1 TO EXHIBIT A-3	 
	EXHIBIT
    B	 

 

    	 	 	 

    	 		 

    

 

SHARE
PURCHASE AGREEMENT

 

THIS
SHARE PURCHASE AGREEMENT, dated as of June 20, 2016 (this “Agreement”), is by and among VBI Vaccines
Inc., a corporation organized under the laws of British Columbia, Canada (the “Company”), and each investor
identified on the signature pages hereto (each, an “Investor” and collectively, the “Investors”).

 

RECITALS

 

A.       The
Company and each Investor are executing and delivering this Agreement in reliance upon the exemptions from registration afforded
by, in the case of U.S. Investors, Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”),
and Rule 506(b) of Regulation D (“Regulation D”), as promulgated by the United States Securities and Exchange
Commission (the “SEC”) thereunder, and, in the case of non-U.S. Investors, Regulation S (“Regulation
S”), as promulgated by the SEC under the Securities Act.

 

B.       Each
Investor, severally and not jointly, wishes to purchase, and the Company wishes to sell, upon the terms and subject to the conditions
stated in this Agreement, that aggregate number of the Company’s common shares, no par value per share (“Common
Shares”), determined in accordance with Section 2.2(c) (the aggregate amount of Common Shares purchased by all
Investors together, the “Purchased Shares”).

 

NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration
the receipt and adequacy of which are hereby acknowledged, the Company and the Investors, intending to be legally bound hereby,
agree as follows:

 

Article
I

DEFINITIONS

 

1.1
Definitions. In addition to the terms defined elsewhere in this Agreement, the following terms have
the meanings indicated:

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 144 under the Securities Act.

 

“Agreement”
has the meaning set forth in the Preamble.

 

“Business
Day” means a day except (i) a Saturday, (ii) a Sunday, (iii) any day on which the SEC or banks in the City of New York
are authorized or required by law to be closed or (iv) a statutory or civic holiday in Vancouver, British Columbia.

 

“Closing”
means the closing of the purchase and sale of the Purchased Shares pursuant to Section 2.1.

 

“Closing
Date” means the date on which all of the conditions set forth in Article V (other than those to be satisfied
at the Closing) shall have been satisfied or waived.

 

    	 	1	 

    	 		 

    

 

“Commission”
means the U.S. Securities and Exchange Commission.

 

“Common
Shares” has the meaning set forth in the Recitals.

 

“Company”
has the meaning set forth in the Preamble.

 

“Company
Financial Statements” has the meaning set forth in Section 3.1(g).

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended.

 

“FINRA”
has the meaning set forth in Section 3.2(d).

 

“GAAP”
means United States generally accepted accounting principles.

 

“IFRS”
means International Financial Reporting Standards, as adopted by the International Accounting Standards Board, consistently applied
during the periods involved.

 

“Indebtedness”
means, with respect to any Person, without duplication (A) all indebtedness for borrowed money, (B) all obligations issued, undertaken
or assumed as the deferred purchase price of property or services (other than trade payables entered into in the ordinary course
of business), (C) all reimbursement or payment obligations with respect to letters of credit, surety bonds and other similar instruments,
(D) all obligations evidenced by notes, bonds, debentures or similar instruments, including obligations so evidenced incurred
in connection with the acquisition of property, assets or businesses, (E) all indebtedness created or arising under any conditional
sale or other title retention agreement, or incurred as financing, in either case with respect to any property or assets acquired
with the proceeds of such indebtedness (even though the rights and remedies of the seller or bank under such agreement in the
event of default are limited to repossession or sale of such property), (F) all monetary obligations under any leasing or similar
arrangement which is classified as a capital lease, and (G) all indebtedness referred to in clauses (A) through (F) above secured
by (or for which the holder of such indebtedness has an existing right, contingent or otherwise, to be secured by) any mortgage,
lien, pledge, charge, security interest or other encumbrance upon or in any property or assets (including accounts and contract
rights) owned by such Person, even though such Person which owns such assets or property has not assumed or become liable for
the payment of such indebtedness.

 

“Indemnified
Person” has the meaning set forth in Section 6.2.

 

“Investment
Amount” has the meaning set forth in Section 2.2(a).

 

“Investor”
has the meaning set forth in the Preamble.

 

“Investor
Party” has the meaning set forth in Section 6.1.

 

“Lien”
means any lien, charge, claim, security interest, pledge encumbrance, right of first refusal, preemptive right or other restriction.

 

    	 	2	 

    	 		 

    

 

“Material
Adverse Effect” means any condition, circumstance, or situation that may result in, or reasonably be expected to result
in (i) a material adverse effect on the legality, validity or enforceability of this Agreement or any of the Transaction Documents,
(ii) a material adverse effect on the results of operations, assets, business or condition (financial or otherwise) of the Company
and its Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company’s ability to perform its obligations
hereunder or under any of the Transaction Documents in any material respect on a timely basis; provided, however, that with respect
to the immediately preceding clause (ii), none of the following shall be deemed in themselves to constitute, and none of the following
shall be taken into account in determining whether there has been, a Material Adverse Effect: (a) any change generally affecting
the economy, financial markets or political, economic or regulatory conditions in the United States, the State of Israel or any
other geographic region in which the Company and its subsidiaries conduct business (except, in each case, to the extent that the
Company or such subsidiary is disproportionately adversely affected relative to other participants in the industries in which
the Company or such subsidiary participate), (b) general financial, credit or capital market conditions, including interest rates
or exchange rates, or any changes therein, (c) conditions (or changes therein) in any industry or industries in which the Company
operates (including seasonal fluctuations) to the extent that such conditions do not disproportionately have a greater adverse
impact on the Company and its subsidiaries, taken as a whole, relative to other companies operating in such industry or industries,
(d) the announcement or pendency of this Agreement and the transactions contemplated hereby or (e) changes in applicable law,
GAAP or IFRS (or, in each case, any interpretations thereof).

 

“Material
Contract” means any contract of the Company that has been filed or was required to have been filed pursuant to Item
601(b)(10) of Regulation S-K or Section 12.2 of National Instrument 51-102 – Ongoing Requirements for Issuers and Insiders,
as applicable.

 

“NI
45-106” has the meaning set forth in Section 3.2(f).

 

“Person”
means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization,
a government or any department or agency thereof and any other legal entity.

 

“PCMLTFA”
has the meaning set forth in Section 3.2(v).

 

“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, a partial proceeding, such as a deposition),
whether commenced or threatened in writing.

 

“Public
Disclosure Record” means the Registration Statement on Form F-4 filed by the Company with the Commission (Registration
No. 333-208761) as declared effective by the Commission on April 8, 2016 and all documents and information filed by the Company
under applicable securities laws on the System for Electronic Document Analysis Retrieval (SEDAR) and on the Electronic Data Gathering,
Analysis, and Retrieval system (EDGAR), during the period commencing on the effective date of such Registration Statement and
ending on the Closing Date.

 

    	 	3	 

    	 		 

    

 

“Purchase
Price” means $4.1624 per Common Share.

 

“Purchased
Shares” has the meaning set forth in the Recitals.

 

“Regulation
D” has the meaning set forth in the Recitals.

 

“Representatives”
has the meaning set forth in Section 7.14.

 

“Required
Approvals” has the meaning set forth in Section 3.1(o).

 

“Rule
144” means Rule 144 promulgated by the SEC under the Securities Act.

 

“SEC”
has the meaning set forth in the Recitals.

 

“Securities
Act” has the meaning set forth in the Recitals.

 

“Short
Sales” means and includes, without limitation, all “short sales” as defined in Rule 200 promulgated under
Regulation SHO under the Exchange Act and all types of direct and indirect stock pledges, forward sale contracts, options, puts,
calls, short sales, swaps, derivatives and similar arrangements (including on a total return basis), and sales and other transactions
through non-U.S. broker-dealers or foreign regulated brokers.

 

“Subsidiary”
means any corporation, association or other business entity of which the entity in question: (i) owns or controls fifty percent
(50%) or more of the outstanding equity securities either directly or through an unbroken chain of entities as to each of which
fifty percent (50%) or more of the outstanding equity securities is owned directly or indirectly by its parent (provided, that
there shall not be included any such entity the equity securities of which are owned or controlled in a fiduciary capacity); (ii)
in the case of partnerships, serves as a general partner; (iii) in the case of a limited liability company, serves as a manager
or a managing member; (iv) otherwise has the ability to elect a majority of the directors, trustees, managers, or managing members
thereof; or (v) under GAAP or IFRS, as applicable, consolidates in its financial statements.

 

“Trading
Day” means (i) a day on which the Common Shares are traded on the Trading Market or (ii) if the Common Shares are not
listed or quoted on the Trading Market, a day on which the Common Shares are quoted in the over-the-counter market as reported
by the Pink Sheets LLC (or any similar organization or agency succeeding to its functions of reporting prices); provided, that
in the event that the Common Shares are not listed or quoted as set forth in the immediately preceding clauses (i) or (ii), then
Trading Day shall mean a Business Day.

 

“Trading
Market” means the NASDAQ Capital Market.

 

“Transaction”
has the meaning set forth in Section 3.2(o).

 

“Transaction
Documents” means this Agreement, including the schedules and exhibits attached hereto, and each of the other agreements
or instruments entered into or executed by the parties hereto in connection with the transactions contemplated by this Agreement.

 

    	 	4	 

    	 		 

    

 

“Transfer
Agent” means Computershare Investor Services Inc. or any successor transfer agent for the Company.

 

“TSX”
means the Toronto Stock Exchange.

 

Article
II

PURCHASE AND SALE

 

2.1
(a)Closing. 

 

Subject
to the terms and conditions set forth in this Agreement, at the Closing, the Company shall issue and sell to each Investor, and
such Investor shall, severally and not jointly with any other Investor, purchase from the Company, such number of Purchased Shares
determined in accordance with Section 2.2(c). The date and time of the Closing shall be 10:00 a.m., New York City Time,
on the Closing Date. The Closing shall take place by electronic communication and delivery of the items to be delivered at Closing
by facsimile or other electronic transmission.

 

(b)       Dilutive
Issuances.

 

(1)       For
purposes of this Section 2.1(b), the following terms shall have the following meanings:

 

(A)       “Common
Share Equivalents” means any securities of the Company which would entitle the holder thereof to acquire at any time
Common Shares, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive Common Shares.

 

(B)       “Exempt
Issuance” means any issuance of (1) shares of capital stock upon any reclassification, stock split or combination, stock
dividend or similar proportionately applied change to the Company’s outstanding capital stock; (2) Common Shares or Common
Share Equivalents to employees, consultants, officers or directors of the Company pursuant to any stock or option plan duly adopted
for such purpose by the Board of Directors of the Company or a committee of directors established for such purpose; (3) securities
issued upon exercise, conversion or exchange of Common Share Equivalents outstanding as of the date of this Agreement, provided
that such securities and any term thereof have not been amended since the date of this Agreement to increase the number of securities
or to decrease the issue price, exercise price, exchange price or conversion price of such securities, (4) securities issued pursuant
to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that
any such issuance shall only be to an entity (or to the equity holders of an entity) which is, itself or through its subsidiaries
or affiliates, an operating company or an owner of an asset in a business synergistic with the business of the Company or its
Subsidiaries and shall provide to the Company or its Subsidiaries benefits in addition to the investment of funds.

 

    	 	5	 

    	 		 

    

 

(2)       If
at any time within 12 months from the date of this Agreement, the Company issues additional Common Shares or Common Share Equivalents,
excluding any shares issued in connection with an Exempt Issuance, at a purchase price per share less than the Purchase Price
(a “Dilutive Issuance”), each Investor shall be entitled to receive without additional consideration such number
of additional Common Shares (the “Supplemental Shares”) equal to the number determined by dividing such Investor’s
Investment Amount by the “Revised Purchase Price” (as derived based on the formula below), less the number
of Purchased Shares purchased by such Investor and any Supplemental Shares previously issued to such Investor as a result of any
prior Dilutive Issuance.

 

CP2
= CP1 x (A+B) / (A+C)

 

“CP2”=Revised
Purchase Price

 

“CP1”=Original
Purchase Price

 

“A”=Number
of Common Shares outstanding on a fully diluted basis immediately prior to such Dilutive Issuance;

 

“B”=Number
of Common Shares that would have been issued if such additional Common Shares or Common Share Equivalents issued in the Dilutive
Issuance had been issued at a price per share equal to CP1 (determined by dividing the aggregate consideration received by the
Company in respect of such issue by CP1); and

 

“C”=Number
of shares of stock issued in the Dilutive Issuance.

 

Notwithstanding
anything herein to the contrary, in no event shall: (a) the Purchased Shares, when aggregated with the Supplemental Shares, exceed:
(i) 19.99% of the issued and outstanding Common Shares as of the date of this Agreement (the “Cap Amount”);
or (ii) with respect to Purchased Shares and Supplemental Shares issued or issuable to insiders of the Company (as contemplated
by Section 3.2(h)), 10% of the issued and outstanding Common Shares as of the date of this Agreement (the “Insider Cap
Amount”); or (iii) with respect to Purchased Shares and Supplemental Shares issued or issuable to a Person or “group”
within the meaning of Section 13(d) of the Exchange Act, when aggregated with all other Common Shares beneficially owned by such
Person or group within the meaning of Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder,
20% of the issued and outstanding Common Shares as of the date of this Agreement (the “Change of Control Cap Amount”)
if the issuance of Supplemental Shares to such Person or “group” would cause such Person or “group” to
become the largest shareholder position of the Company, or (b) the Revised Purchase Price be less than 85% of the Purchase Price
(the “Floor Price”). In the event: (a) the number of Supplemental Shares issuable pursuant to this Section
2.1(b), when aggregated with the Purchased Shares, would exceed the Cap Amount or the Insider Cap Amount or the Change of Control
Cap Amount, as applicable (the “Excess Shares”), or (b) in the event the Revised Purchase Price is less than
the Floor Price, then the Company shall use its reasonable best efforts to obtain shareholder approval as soon as commercially
practicable after the Dilutive Issuance to issue the Excess Shares or approve the Revised Purchase Price in accordance with the
requirements of the Trading Market and the TSX, if applicable, and in such event the Excess Shares shall not be issued until or
unless such shareholder approval is duly obtained. Any Supplemental Shares available for issuance without exceeding the Cap Amount
or the Insider Cap Amount, as applicable, shall be apportioned among and issued to the Investors on a pro rata basis based on
the ratio of such Investor’s Investment Amount to the aggregate Investment Amount of all the Investors combined.

 

    	 	6	 

    	 		 

    

 

The
requirements of this Section 2.1(b) shall apply upon the occurrence of each successive Dilutive Issuance, subject to the limitations
set forth in the preceding paragraph.

 

2.2       Pre-Closing
and Closing Deliveries; Irrevocable Subscription.

 

(a)       Prior
to the Closing, each Investor shall deliver to a Company account, pursuant to the wire instructions which are provided as Exhibit
B hereto (the “Company Account”), the aggregate amount such Investor desires to invest in Purchased Shares,
as set forth on such Investor’s signature page to this Agreement, in U.S. dollars and in immediately available funds (the
“Investment Amount”), which Investment Amount shall be returned to the Investor by the Company solely in the
event of a termination of this Agreement pursuant to Section 7.1.

 

(b)       At
or prior to the Closing, each Investor shall also deliver or cause to be delivered to the Company the following:

 

(i)       a
completed and executed Investor signature page to this Agreement;

 

(ii)       a
completed Investor Questionnaire in the form attached hereto as Exhibit A-1;

 

(iii)       a
completed and executed copy of the Investor Certificate attached hereto as Exhibit A-2; and

 

(iv)       a
completed and executed copy of the Canadian Investor Certificate attached hereto as Exhibit A-3.

 

(c)       At
the Closing, the Company shall deliver or cause to be delivered to each Investor a copy of the Company’s instructions to
its Transfer Agent, instructing the Transfer Agent to issue in book entry form, inclusive of such restrictive and other legends
as set forth in Section 4.1, a number of Purchased Shares equal to such Investor’s Investment Amount divided by the
Purchase Price (rounded down to the nearest whole share), registered in the name of such Investor. The Company shall, promptly
following Closing, return to each Investor the balance of such Investor’s Investment amount,
if any, that would have otherwise been used to acquire a fractional Common Share.

 

(d)       Each
Investor acknowledges and agrees that such Investor’s delivery of each item required to be delivered by such Investor pursuant
to Section 2.2(a) and Section 2.2(b) is irrevocable prior to Closing, unless and until this Agreement is terminated
in accordance with Section 7.1.

 

    	 	7	 

    	 		 

    

 

Article
III

REPRESENTATIONS AND WARRANTIES

 

3.1
Representations and Warranties of the Company. The Company hereby represents and warrants to the Investors as follows:

 

(a)       Subsidiaries.
The Company owns, directly or indirectly, all of the capital stock or comparable equity interests of each Subsidiary free and
clear of any Lien (other than restrictions on transfer arising under applicable securities laws), and all issued and outstanding
shares of capital stock or comparable equity interest of each Subsidiary are validly issued and are fully paid, non-assessable
and free of preemptive and similar rights.

 

(b)       Organization
and Qualification. The Company and each Subsidiary is an entity duly organized, validly existing and in good standing under
the laws of the jurisdiction of its incorporation or organization, as applicable, with the requisite power and legal authority
to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary
is in violation of any of the provisions of its certificate or articles of incorporation, bylaws or other organizational or charter
documents, as applicable. The Company and each Subsidiary is duly qualified to do business and is in good standing as a foreign
corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such
qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, would not, individually
or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect and no Proceeding has been instituted
seeking to revoke, limit or curtail such power or authority or qualification.

 

(c)       Authorization;
Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by each of the Transaction Documents to which it is a party and otherwise to carry out its obligations hereunder
and thereunder. The execution and delivery by the Company of each of the Transaction Documents to which it is a party and the
consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary corporate action
on the part of the Company, and no further consent or action is required by the Company, its Board of Directors or its shareholders.
Each of the Transaction Documents to which it is a party has been (or upon delivery will be) duly executed by the Company and
is, or when delivered in accordance with the terms hereof, will constitute, the valid and binding obligation of the Company enforceable
against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy,
insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights
generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable
remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.

 

    	 	8	 

    	 		 

    

 

(d)       No
Conflicts. The execution, delivery and performance by the Company of the Transaction Documents to which it is a party, the
issuance and sale of the Purchased Shares and the consummation by the Company of the transactions contemplated hereby and thereby
do not, and will not, (i) conflict with or violate any provision of the Company’s or any Subsidiary’s certificate
or articles of incorporation, bylaws or other organizational or charter documents, as applicable, (ii) conflict with, or constitute
a default (or an event that with notice or lapse of time or both would become a default) under, or give to others any rights of
termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement (including
any Material Contract), credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other
understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary
is bound, or affected, except to the extent that such conflict, default, termination, amendment, acceleration or cancellation
right would not have or reasonably be expected to result in a Material Adverse Effect, or (iii) result in a violation of any law,
rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the
Company or any Subsidiary is subject or by which any material property or asset of the Company or any Subsidiary is bound or affected,
except to the extent that such violation would not have or reasonably be expected to result in a Material Adverse Effect.

 

(e)       The
Purchased Shares. The Purchased Shares are duly authorized and, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens (other than
restrictions on transfer arising under applicable securities laws) and will not be subject to preemptive or similar rights of
shareholders (other than those imposed by the Investors).

 

(f)       Capitalization.
All outstanding shares of capital stock of the Company and of each Subsidiary are duly authorized, validly issued, fully paid
and nonassessable and have been issued in compliance in all material respects with all applicable securities laws, and none of
such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase any capital
stock of the Company or such Subsidiary.

 

(g)       Securities
Laws Matters; Financial Statements. The Company has filed all documents required to be filed by it in accordance with applicable
securities laws with the TSX and all other applicable regulatory authorities. All such documents and information comprising the
Public Disclosure Record, as of their respective dates (or, if amended, as of the date of such amendment), (1) did not contain
any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances in which they were made, not misleading, and (2) complied in all material respects
with the requirements of applicable securities laws, and any amendments to the Public Disclosure Record required to be made have
been filed on a timely basis with the applicable regulatory authorities and the TSX. The Company has not filed any confidential
material change report with any applicable regulatory authorities or the TSX that at the date of this Agreement remains confidential.
The Company’s audited consolidated financial statements as at and for the fiscal years ended December 31, 2015 and 2014
(including the notes thereto), as included in the Public Disclosure Record (collectively, the “Company Financial Statements”),
were prepared in accordance with IFRS consistently applied (except (i) as otherwise indicated in such financial statements and
the notes thereto or, in the case of audited statements, in the related report of the Company’s independent auditors, or
(ii) in the case of unaudited interim statements, are subject to normal period-end adjustments (none of which are material, individually
or in the aggregate) and may omit notes which are not required by applicable laws in the unaudited statements) and present fairly
in all material respects the consolidated financial condition, results of operations, changes in financial position of the Company
and its Subsidiaries as of the dates thereof and for the periods indicated therein (subject, in the case of any unaudited interim
financial statements, to normal period-end adjustments, none of which are material, individually or in the aggregate) and reflect
reserves required by IFRS or GAAP, as applicable, in respect of all material contingent liabilities, if any, of the Company and
its Subsidiaries on a consolidated basis. Other than the Company changing its accounting principles from IFRS to GAAP commencing
with the first quarter of 2016, there has been no material change in the Company’s accounting policies, except as described
in the notes to the Company Financial Statements, since December 31, 2015. All Material Contracts to which the Company or any
Subsidiary is a party or to which the property or assets of the Company or any Subsidiary are subject are included as part of
or identified in the Public Disclosure Record.

 

    	 	9	 

    	 		 

    

 

(h)       Absence
of Litigation. Except as disclosed in the Public Disclosure Record, there is no action, suit, claim, or Proceeding pending,
or, to the Company’s knowledge, threatened, before or by any court, public board, government agency, self-regulatory organization
or body that adversely affect or challenge the legality, validity or enforceability of any of the Transaction Documents or that
would, individually or in the aggregate, have or be reasonably likely to result in a Material Adverse Effect.

 

(i)       Compliance.
Except as would not, individually or in the aggregate, have or be reasonably likely to result in a Material Adverse Effect, (i)
neither the Company nor any Subsidiary is in default under or in violation of (and no event has occurred that has not been waived
that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company
or any Subsidiary received written notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement (including any Material Contract) or instrument to which it is a party or by which
it or any of its properties is bound (whether or not such default or violation has been waived), (ii) neither the Company nor
any Subsidiary is in violation of any order of any court, arbitrator or governmental body, or (iii) neither the Company nor any
Subsidiary is or has been in violation of any statute, rule or regulation of any governmental authority.

 

(j)       Title
to Assets. Neither the Company nor any Subsidiary owns real property. The Company and each Subsidiary has good and marketable
title in all personal property owned by them that is material to the business of the Company and each Subsidiary, in each case
free and clear of all Liens, except for Liens that do not, individually or in the aggregate, have or are reasonably likely to
result in a Material Adverse Effect. Any real property and facilities held under lease by the Company or any Subsidiary is held
by it under valid, subsisting and enforceable leases of which the Company and each Subsidiary is in material compliance.

 

(k)       Intellectual
Property. The Company and its subsidiaries own or possess adequate rights or licenses to use all material trademarks, trade
names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals,
governmental authorizations, trade secrets and rights necessary to conduct their respective businesses as now conducted. Except
for matters described in the Public Disclosure Record, or matters which would not be reasonably likely to have a Material Adverse
Effect, the Company and its Subsidiaries do not have any knowledge of any violation or infringement by the Company or its Subsidiaries
of trademark, trade name rights, patents, patent rights, copyrights, inventions, licenses, service names, service marks, service
mark registrations, trade secret or other similar rights of others, and, to the knowledge of the Company, there is no claim, action
or Proceeding being made or brought against, or to the Company’s knowledge, being threatened against, the Company or its
subsidiaries regarding trademark, trade name, patents, patent rights, invention, copyright, license, service names, service marks,
service mark registrations, trade secret or other violation or infringement; and the Company and its Subsidiaries are unaware
of any facts or circumstances which might give rise to any of the foregoing. The Company and its Subsidiaries have taken reasonable
security measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure
to do so would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

    	 	10	 

    	 		 

    

 

(l)       Insurance.
The Company and each Subsidiary is insured by insurers of recognized financial responsibility against such losses and risks and
in such amounts as are prudent and customary in the businesses and locations in which the Company and each Subsidiary is engaged.
Neither the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage
as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business.

 

(m)       Internal
Accounting Controls. The Company and each Subsidiary maintain a system of internal accounting controls sufficient to provide
reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations,
(ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted
accounting principles and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s
general or specific authorization and (iv) the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences.

 

(n)       Indebtedness.
Except as disclosed in the Public Disclosure Record, neither the Company nor any Subsidiary (i) has any outstanding Indebtedness,
(ii) is in violation of any term of and is not in default under any contract, agreement or instrument relating to any Indebtedness,
except where such violations and defaults would not result, individually or in the aggregate, in a Material Adverse Effect or
(iii) is a party to any contract, agreement or instrument relating to any Indebtedness, the performance of which, in the reasonable
judgment of the Company’s officers, would have or is expected to result in a Material Adverse Effect.

 

(o)       Filings,
Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice
to, or make any filing or registration with, any court or other federal, state, local, provincial or other governmental authority
or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents (including
the issuance of the Purchased Shares), other than (i) filings required by applicable securities laws, (ii) the filing of a Notice
of Sale of Securities on Form D with the SEC under Regulation D, (iii) the filing with the securities commissions in the applicable
jurisdictions in Canada, within 10 days from the date of the sale of the Purchased Shares, of a Form 45-106F1 or Form 45-106F6,
as applicable, prepared and executed in accordance with applicable securities laws and accompanied by the prescribed fees, if
any, (iv) the filing of any requisite notices and/or application(s) to the applicable Trading Market, any national securities
exchange or the TSX for the issuance and sale of the Purchased Shares and the listing of the Purchased Shares for trading or quotation,
as the case may be, thereon in the time and manner required thereby and (v) those that have been made or obtained prior to the
date of this Agreement (collectively, the “Required Approvals”).

 

    	 	11	 

    	 		 

    

 

(p)       Certain
Fees. Except with respect to compensation payable to Laidlaw & Company (UK) Ltd. and any of the Company’s officers,
directors and employees, no brokerage or finder’s fees or commissions are or will be payable by the Company or any Subsidiaries
to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect
to the transactions contemplated by the Transaction Documents. The Investors shall have no obligation with respect to any fees
or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section 3.1
that may be due in connection with the transactions contemplated by the Transaction Documents.

 

(q)       Private
Placement. Assuming the accuracy of the Investors’ representations and warranties set forth in Section 3.2 and
their compliance with their agreements contained in this Agreement, no registration under the Securities Act is required for the
offer and sale of the Purchased Shares by the Company to the Investors pursuant to the terms of this Agreement.

 

(r)       No
General Solicitation. Neither the Company nor any person acting on behalf of the Company has offered or sold any of the Purchased
Shares by any form of general solicitation or general advertising.

 

3.2
Representations and Warranties of the Investors. Each Investor hereby, as to itself only and for no other Investor, represents
and warrants to the Company as follows:

 

(a)       Organization;
Authority. Such Investor, if such Investor is not a natural person, is an entity duly organized, validly existing and in good
standing under the laws of the jurisdiction of its organization with the requisite corporate, limited liability company, partnership
or other power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise
to carry out its obligations hereunder and thereunder. The purchase by such Investor of the Purchased Shares hereunder and the
consummation of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate,
partnership or other action on the part of such Investor. This Agreement and the Transaction Documents to which such Investor
is a party or has or will execute have been duly executed and delivered by such Investor and constitute the valid and binding
obligations of such Investor, enforceable against it in accordance with their terms, except (i) as limited by general equitable
principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement
of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive
relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law.

 

(b)       Legal
Capacity. If the Investor is an individual, the Investor is of the full age of majority in the jurisdiction in which this
Agreement is executed and is legally competent to execute, deliver and be bound by this Agreement, to perform all of its obligations
hereunder and to undertake all actions required of the Investor hereunder.

 

    	 	12	 

    	 		 

    

 

(c)       No
Public Sale or Distribution. Such Investor is acquiring the Purchased Shares in the ordinary course of business for its own
account and not with a view towards, or for resale in connection with, the public sale or distribution thereof, except pursuant
to sales registered under the Securities Act or under an exemption from such registration and in compliance with applicable securities
laws, and such Investor does not have a present arrangement to effect any distribution of any of the Purchased Shares to or through
any person or entity.

 

(d)       Non-U.S.
Person. If such Investor’s address as set forth on such Investor’s signature page to this Agreement is not a U.S.
address, then such investor represents and warrants that he, she or it is not a “U.S. person” as defined in
Rule 902 of Regulation S.

 

(e)       Accredited
Investor; Investor Status. Such Investor is an “accredited investor” as defined in Rule 501(a) under the Securities
Act or a “qualified institutional buyer” as defined in Rule 144A(a) under the Securities Act. Such Investor is not
a registered broker dealer registered under Section 15(a) of the Exchange Act, or a member of the Financial Industry Regulatory
Authority, Inc. (“FINRA”) or an entity engaged in the business of being a broker dealer. Except as otherwise
disclosed in writing to the Company in such Investor’s Questionnaire, such Investor is not affiliated with any broker dealer
registered under Section 15(a) of the Exchange Act, or a member of the FINRA or an entity engaged in the business of being a broker
dealer.

 

(f)       Canadian
Prospectus Exemption. Such Investor is purchasing the Purchased Shares with the benefit of the prospectus exemption provided
by Section 2.3 of National Instrument 45-106 – Prospectus Exemptions (“NI 45-106”) (that is, such
Investor is purchasing as principal and is an “accredited investor” within the meaning of Section 1.1 of NI 45-106);
and is either purchasing the Purchased Shares as principal for its own account, or is deemed to be purchasing the Purchased Shares
as principal for its own account in accordance with applicable securities laws.

 

(g)       Creation
of Accredited Investor Status. If the Investor is an “accredited investor” in reliance on paragraph (m) of the
definition of “accredited investor” in section 1.1 of NI 45-106, the Investor was not created or used solely to purchase
or hold securities as an accredited investor under that paragraph (m).

 

(h)       Insider
Status. Such Investor either (A) is not an “insider” of the Company or a “registrant” (each as defined
under applicable British Columbia securities laws) or (B) has identified itself to the Company as either an “insider”
or a “registrant” (each as defined under applicable British Columbia securities laws).

 

    	 	13	 

    	 		 

    

 

(i)       Purchasers
in Jurisdictions other than the U.S. and Canada. If the Investor, or any beneficial person for whom the Investor is acting,
is a resident of or otherwise subject to the securities legislation of a jurisdiction other than the U.S. and Canada:

 

(i)       it
is knowledgeable of, or has been independently advised so as to, the applicable securities legislation in the jurisdiction of
its residence which would apply to this Agreement. The delivery of this Agreement and the purchase of the Purchased Shares by
such Investor does not contravene the applicable laws (including applicable securities legislation) in the jurisdiction in which
it is resident or to which it is subject and does not trigger any obligation to prepare and file a prospectus, registration statement
or similar document, or any other report with respect to such purchase, or any registration or other obligation or reporting requirement
on the part of the Company, and it will provide such evidence of compliance with all such matters as the Company may request;
and

 

(ii)       the
Investor certifies that it is not resident in British Columbia and acknowledges that (a) no securities commission or similar regulatory
authority has reviewed or passed on the merits of the Purchased Shares; (b) there is no government or other insurance covering
the Purchased Shares; (c) there are risks associated with the purchase of the Purchased Shares; (d) there are restrictions on
the Investor’s ability to resell the Purchased Shares and it is the responsibility of the Investor to find out what those
restrictions are and to comply with them before selling the Purchased Shares; and (e) the Company has advised the Investor that
the Company is relying on an exemption from the requirements to provide the Investor with a prospectus and to sell the Purchased
Shares through a person registered to sell securities under the Securities Act (British Columbia) and, as a consequence
of acquiring securities pursuant to this exemption, certain protections, rights and remedies provided by the Securities Act
(British Columbia), including statutory rights of rescission or damages, will not be available to the Investor;

 

(j)       General
Solicitation. Such Investor is not purchasing the Purchased Shares as a result of any advertisement, article, notice or other
communication regarding the Purchased Shares published in any newspaper, magazine or similar media, broadcast over television
or radio, disseminated over the Internet or presented at any seminar or any other general solicitation or general advertisement.
Neither such Investor, nor any Person acting on behalf of such Investor, has offered or sold, and does not presently intend to
offer and sell at any future time, any Purchased Shares by any form of general solicitation or general advertising.

 

(k)       Experience
of Such Investor; Risk of Loss. Such Investor has such knowledge, sophistication and experience in business and financial
matters so as to be capable of evaluating the merits and risks of the prospective investment in the Purchased Shares, and has
so evaluated the merits and risks of such investment. Such Investor understands that it must bear the economic risk of its investment
in the Purchased Shares indefinitely, and is able to bear such risk and is able to afford a complete loss of such investment.
Such Investor has the ability to bear the economic risks of its prospective investment in the Purchased Shares and can afford
the complete loss of such investment.

 

(l)       Access
to Information. Such Investor acknowledges that it has reviewed this Agreement and the Public Disclosure Record and has been
afforded: (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives
of the Company concerning the Company and the terms and conditions of the offering of the Purchased Shares and the merits and
risks of investing in the Purchased Shares; (ii) access to information (other than material non-public information) about the
Company and each Subsidiary and its financial condition, results of operations, business, properties, management and prospects
sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company
possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with
respect to the investment.

 

    	 	14	 

    	 		 

    

 

(m)       No
Governmental Review. Such Investor understands that no U.S. federal or state agency, provincial securities commissions or
similar regulatory authority in Canada or any other government or governmental agency has passed on or made any recommendation
or endorsement of the Purchased Shares or the fairness or suitability of the investment in the Purchased Shares nor have such
authorities passed upon or endorsed the merits of the offering of the Purchased Shares. Such Investor acknowledges that there
is no government or other insurance covering the Purchased Shares.

 

(n)       No
Conflicts. The execution, delivery and performance by such Investor of this Agreement and the consummation by such Investor
of the transactions contemplated hereby will not (i) result in a violation of the organizational documents of such Investor or
(ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under,
or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument
to which such Investor is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including
securities laws) applicable to such Investor, except in the case of clauses (ii) and (iii) above, for such that are not material
and do not otherwise affect the ability of such Investor to consummate the transactions contemplated hereby or perform its obligations
hereunder.

 

(o)       Prohibited
Transactions; Confidentiality. Such Investor has not, directly or indirectly, and no Person acting on behalf of or pursuant
to any understanding with such Investor has, engaged in any purchases or sales in any of the Company’s securities, including
derivatives thereof, including, without limitation, any Short Sales involving any of the Company’s securities (a “Transaction”),
since the time that such Investor was first contacted by the Company or any other Person regarding an investment in the Company.
Such Investor covenants that neither it nor any Person acting on its behalf or pursuant to any understanding with such Investor
will engage, directly or indirectly, in any Transactions in the securities of the Company prior to the time the transactions contemplated
by this Agreement are publicly disclosed.

 

(p)       No
Legal, Tax or Investment Advice. Such Investor understands and agrees that nothing in this Agreement or any other materials
presented by or on behalf of the Company to such Investor in connection with the purchase of the Purchased Shares constitutes
legal, tax or investment advice. Such Investor has consulted such legal, tax and investment advisors as it, in its sole discretion,
has deemed necessary or appropriate in connection with its purchase of the Purchased Shares and has made its own assessment and
has satisfied itself concerning the relevant tax and other economic considerations relevant to its investment in the Purchased
Shares.

 

    	 	15	 

    	 		 

    

 

(q)       Reliance
on Exemptions. Such Investor understands that the Purchased Shares are being offered and sold to it in reliance on specific
exemptions from the registration requirements of applicable securities laws, including the requirements to provide the Investor
with a prospectus and to sell securities through a person registered to sell securities under applicable Canadian securities laws,
and that the Company is relying upon the truth and accuracy of, and such Investor’s compliance with, the representations,
warranties, agreements, acknowledgments and understandings of such Investor set forth herein and in the other Transaction Documents
in order to determine the availability of such exemptions and the eligibility of such Investor to acquire the Purchased Shares.
As a result of acquiring the Purchased Shares pursuant to such exemptions:

 

(i)       such
Investor may be restricted from using some of the protections, rights and remedies otherwise available under applicable Canadian
securities laws, including statutory rights of rescission or damages in the event of a misrepresentation;

 

(ii)       such
Investor may not receive information that would otherwise be required to be provided to it under applicable Canadian securities
laws; and

 

(iii)       the
Company is relieved from certain obligations that would otherwise apply under applicable Canadian securities laws.

 

(r)       Residency.
Such Investor is a resident of that jurisdiction specified on such Investor’s signature page to this Agreement.

 

(s)       Transfer
or Resale. Such Investor understands that: (i) the Purchased Shares have not been and are not being registered under the Securities
Act, any U.S. state securities laws or the laws of any foreign country or other jurisdiction, and may not be offered for sale,
sold, assigned or transferred unless (A) subsequently registered thereunder or (B) such Investor shall have delivered to the Company
an opinion of counsel, in a form reasonably acceptable to the Company, to the effect that such Purchased Shares to be sold, assigned
or transferred may be sold, assigned or transferred pursuant to an exemption from such registration; (ii) any sale of the Purchased
Shares made in reliance on Rule 144 may be made only in accordance with the terms of Rule 144 and further, if Rule 144 is not
applicable, any resale of the Purchased Shares under circumstances in which the seller (or the Person through whom the sale is
made) may be deemed to be an underwriter (as that term is defined in the Securities Act) may require compliance with some other
exemption under the Securities Act or the rules and regulations of the SEC thereunder or any other limited exemptions and requirements
under applicable Canadian securities laws; and (iii) neither the Company nor any other Person is under any obligation to register
the Purchased Shares under the Securities Act, any state securities laws or any foreign securities laws or to comply with the
terms and conditions of any exemption thereunder.

 

    	 	16	 

    	 		 

    

 

(t)       U.S.
Legends. Such Investor understands that the certificates or other instruments representing the Purchased Shares, except as
set forth below, shall bear any legend as required by the “blue sky” laws of any state and restrictive legends in
substantially the following forms (and a stop-transfer order may be placed against transfer of such stock certificates):

 

THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND
MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS (I) AS PART OF THEIR
DISTRIBUTION AT ANY TIME OR (II) OTHERWISE UNTIL SIX MONTHS AFTER THE LATER OF THE COMMENCEMENT OF THE OFFERING THEREOF AND THE
CLOSING DATE, EXCEPT IN EITHER CASE IN ACCORDANCE WITH REGULATION S UNDER THE SECURITIES ACT. NO HEDGING TRANSACTION CAN BE CONDUCTED
WITH REGARD TO THE SECURITIES EXCEPT AS PERMITTED BY THE SECURITIES ACT. TERMS USED ABOVE HAVE THE MEANINGS GIVEN TO THEM BY REGULATION
S PROMULGATED UNDER THE SECURITIES ACT.

 

THESE
SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER ANY APPLICABLE STATE SECURITIES LAWS
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR
PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT
AND IN COMPLIANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS.

 

Such
Investor understands that the legends set forth above shall be removed and the Company shall issue a certificate or other instrument
without such legend to the holder of the Purchased Shares upon which it is stamped, if, unless otherwise required by state securities
laws, (i) such Purchased Shares (x) are registered for resale pursuant to an effective registration statement under the Securities
Act and (y) are resold pursuant to such registration statement or (ii) in connection with a sale, assignment or other transfer
pursuant to Rule 144, such holder provides the Company with an opinion of a law firm reasonably acceptable to the Company, in
a form reasonably acceptable to the Company, to the effect that such sale, assignment or transfer may be made in compliance with
Rule 144.

 

    	 	17	 

    	 		 

    

 

(u)       Canadian
Legends.

 

(i)       Until
the date that is four months and one day following the Closing Date, any physical certificates representing the Purchased Shares
must bear a legend substantially in the following form:

 

UNLESS
PERMITTED UNDER APPLICABLE CANADIAN PROVINCIAL SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY
BEFORE OCTOBER 21, 2016.

 

THE
SECURITIES REPRESENTED BY THIS CERTIFICATE ARE LISTED ON THE TORONTO STOCK EXCHANGE (THE “TSX”); HOWEVER, THE SAID
SECURITIES CANNOT BE TRADED THROUGH THE FACILITIES OF THE TSX SINCE THEY ARE NOT FREELY TRANSFERABLE, AND CONSEQUENTLY ANY CERTIFICATE
REPRESENTING SUCH SECURITIES IS NOT ‘GOOD DELIVERY’ IN SETTLEMENT OF TRANSACTIONS ON THE TSX.

 

(ii)       In
the event that the Purchased Shares are entered into a direct registration or other electronic book entry system, or if the Investor
did not directly receive a certificate representing the Purchased Shares, the Company has hereby provided the Investor with written
notice pursuant to section 2.5(2)(3.1) of National Instrument 45-102 – Resale of Securities that:

 

UNLESS
PERMITTED UNDER APPLICABLE CANADIAN PROVINCIAL SECURITIES LEGISLATION, THE HOLDER OF COMMON SHARES MUST NOT TRADE THE COMMON SHARES
BEFORE OCTOBER 21, 2016.”

 

(v)       Not
Proceeds of Crime. The funds representing the Investment Amount which will be advanced by such Investor hereunder will not
represent proceeds of crime for the purposes of the Proceeds of Crime (Money Laundering) and Terrorist Financing Act (Canada),
as may be amended from time to time (the “PCMLTFA”) and such Investor acknowledges that the Company may in
the future be required by law to disclose such Investor’s name and other information relating to this Agreement and such
Investor’s subscription hereunder, on a confidential basis, pursuant to the PCMLTFA. To the best of its knowledge: (i) none
of the funds representing the Investment Amount to be provided by such Investor: (A) have been or will be derived from or related
to any activity that is deemed criminal under the laws of Canada, the United States or any other jurisdiction, or (B) are being
tendered on behalf of a person or entity who has not been identified to such Investor; and (ii) such Investor shall promptly notify
the Company if such Investor discovers that any of such representations cease to be true, and to provide the Company with appropriate
information in connection therewith.

 

    	 	18	 

    	 		 

    

 

Article
IV

OTHER AGREEMENTS OF THE PARTIES

 

4.1       Transfer
Restrictions.

 

(a)       The
Investors covenant that the Purchased Shares will be disposed of only pursuant to an effective registration statement or prospectus
under, and in compliance with the requirements of, the Securities Act and applicable Canadian securities laws or pursuant to an
available exemption from the registration or prospectus requirements of the Securities Act or applicable Canadian securities laws,
as applicable, and in compliance with applicable state securities laws. In connection with any transfer of Purchased Shares other
than pursuant to an effective registration statement, prospectus or to the Company, the Company may require the transferor to
provide to the Company an opinion of counsel selected by the transferor, the form and substance of which opinion shall be reasonably
satisfactory to the Company, to the effect that such transfer does not require registration under the Securities Act. Notwithstanding
the foregoing, the Company hereby consents to and agrees to register on the books of the Company and with its Transfer Agent,
without any such legal opinion, except to the extent that the Transfer Agent requests such legal opinion, any transfer of Purchased
Shares by an Investor to an Affiliate of such Investor, provided that such transfer does not involve a “sale” within
the meaning of Section 2(a)(3) of the Securities Act and provided that such Affiliate does not request any removal of any existing
legends on any certificate evidencing the Purchased Shares.

 

(b)       The
Investors agree to the imprinting, until no longer required by this Section 4.1, of the legends, in substantially the following
form, on any certificate or other instrument evidencing any of the Purchased Shares:

 

THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND
MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS (I) AS PART OF THEIR
DISTRIBUTION AT ANY TIME OR (II) OTHERWISE UNTIL SIX MONTHS AFTER THE LATER OF THE COMMENCEMENT OF THE OFFERING THEREOF AND THE
CLOSING DATE, EXCEPT IN EITHER CASE IN ACCORDANCE WITH REGULATION S UNDER THE SECURITIES ACT. NO HEDGING TRANSACTION CAN BE CONDUCTED
WITH REGARD TO THE SECURITIES EXCEPT AS PERMITTED BY THE SECURITIES ACT. TERMS USED ABOVE HAVE THE MEANINGS GIVEN TO THEM BY REGULATION
S PROMULGATED UNDER THE SECURITIES ACT.

 

THESE
SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER ANY APPLICABLE STATE SECURITIES LAWS
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR
PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT
AND IN COMPLIANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS.

 

    	 	19	 

    	 		 

    

 

(c)       The
Investors agree that any physical certificates evidencing the Purchased Shares will be endorsed with, or the ownership statement
issued under a direct registration system or other electronic book-entry system will bear, a legend setting out resale restrictions
under applicable Canadian securities laws in substantially the following form:

 

UNLESS
PERMITTED UNDER APPLICABLE CANADIAN PROVINCIAL SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY
BEFORE OCTOBER 21, 2016.

 

Additionally,
the Investors agree that any physical certificates representing the Purchased Shares will be endorsed with a legend setting out
resale restrictions pursuant to policies of the TSX in substantially the following form:

 

THE
SECURITIES REPRESENTED BY THIS CERTIFICATE ARE LISTED ON THE TORONTO STOCK EXCHANGE (THE “TSX”); HOWEVER, THE SAID
SECURITIES CANNOT BE TRADED THROUGH THE FACILITIES OF THE TSX SINCE THEY ARE NOT FREELY TRANSFERABLE, AND CONSEQUENTLY ANY CERTIFICATE
REPRESENTING SUCH SECURITIES IS NOT ‘GOOD DELIVERY’ IN SETTLEMENT OF TRANSACTIONS ON THE TSX.

 

Certificates
or another instrument evidencing the Purchased Shares shall not be required to contain such legend or any other legend (i) following
any sale of such Purchased Shares pursuant to an effective registration statement or prospectus under the Securities Act or Canadian
securities laws, as applicable, (ii) pursuant to Rule 144 if the holder provides the Company with a legal opinion (and the documents
upon which the legal opinion is based) reasonably acceptable to the Company to the effect that the Purchased Shares can be sold
under Rule 144 or (iii) if the holder provides the Company with a legal opinion (and the documents upon which the legal opinion
is based) reasonably acceptable to the Company to the effect that the legend is not required under applicable requirements of
the Securities Act (including controlling judicial interpretations and pronouncements issued by the Staff of the SEC). The Company
may not make any notation on its records or give instructions to the Transfer Agent that expand the restrictions on transfer set
forth in this Section 4.1.

 

Article
V

CONDITIONS

 

5.1
Conditions Precedent to the Obligations of the Investors. The obligation of each Investor to acquire Purchased Shares at
the Closing is subject to the satisfaction, unless waived in writing by such Investor, at or before the Closing, of each of the
following conditions:

 

(a)       Representations
and Warranties. The representations and warranties of the Company contained herein shall be true and correct in all material
respects as of the date when made and as of the Closing Date as though made on and as of the Closing Date (except for those representations
and warranties that speak as of a specific date, which shall be true and correct in all material respects as of such specified
date).

 

    	 	20	 

    	 		 

    

 

 

(b)       Performance.
The Company shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions
required by the Transaction Documents to be performed, satisfied or complied with by it at or prior to the Closing.

 

(c)       Approvals.
The Company shall have obtained all governmental, regulatory or third party consents and approvals, if any, necessary for the
sale of the Purchased Shares (including all Required Approvals), all of which shall be and remain so long as necessary in full
force and effect.

 

(d)       Transaction
Documents. The Company shall have executed each of the Transaction Documents to which it is a party and delivered the same
to the Investors.

 

(e)       No
Injunction. No Proceeding shall have been filed and no statute, rule, regulation, executive order, decree, ruling or injunction
shall have been enacted, entered or promulgated by any court or governmental authority of competent jurisdiction that prohibits
or seeks to prohibit or otherwise challenges the consummation of any of the transactions contemplated by the Transaction Documents.

 

(f)       Closing
Deliveries. The Company shall have delivered or caused to be delivered, all of the items required by Section 2.2(c).

 

5.2
Conditions Precedent to the Obligations of the Company. The obligation of the Company to sell the Purchased Shares at the
Closing is subject to the satisfaction or waiver by the Company, at or before the Closing, of each of the following conditions:

 

(a)       Representations
and Warranties. The representations and warranties of the Investors contained herein shall be true and correct in all material
respects as of the date when made and as of the Closing Date as though made on and as of the Closing Date (except for those representations
and warranties that speak as of a specific date, which shall be true and correct in all material respects as of such specified
date).

 

(b)       Performance.
The Investors shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions
required by the Transaction Documents to be performed, satisfied or complied with by the Investors at or prior to the Closing.

 

(c)       Approvals.
The Company shall have obtained all governmental, regulatory or third party consents and approvals, if any, necessary for the
sale of the Purchased Shares (including all Required Approvals), all of which shall be and remain so long as necessary in full
force and effect.

 

(d)       Deliverables.
The Investors shall have executed each of the Transaction Documents to which it is a party and delivered the same to the Company.
The Investors shall have delivered to the Company those items required by Section 2.2(a) and Section 2.2(b).

 

    	 	21	 

    	 		 

    

 

(e)       No
Injunction. No Proceeding shall have been filed and no statute, rule, regulation, executive order, decree, ruling or injunction
shall have been enacted, entered or promulgated by any court or governmental authority of competent jurisdiction that prohibits
or seeks to prohibit or otherwise challenges the consummation of any of the transactions contemplated by the Transaction Documents.

 

(f)       Closing
Deliveries. The Investors shall have delivered or caused to be delivered, all of the items required by Section 2.2(b).

 

Article
VI

INDEMNIFICATION

 

6.1
Indemnification of Investors. The Company will indemnify and hold each Investor and its directors, officers, shareholders,
members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles
notwithstanding a lack of such title or any other title), each Person who controls such Investor (within the meaning of Section
15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners
or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack
of such title or any other title) of such controlling person (each, an “Investor Party”) harmless from any
and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts
paid in settlements, court costs and reasonable attorneys’ fees and reasonable costs of investigation that any such Investor
Party may suffer or incur, as a result of or relating to third party claims against such Investor relating to any breach of any
of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction
Documents, provided that that such a claim for indemnification relating to any breach of any of the representations or warranties
made by the Company in this Agreement is made within six months from the Closing. The Company will not be liable to any Investor
Party under this Agreement to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any
Investor Party’s breach of any of the representations, warranties, covenants or agreements made by such Investor Party in
this Agreement or in the other Transaction Documents.

 

6.2
Conduct of Indemnification Proceedings. Promptly after receipt by any Person (the “Indemnified Person”)
of notice of any demand, claim or circumstances which would or might give rise to a claim or the commencement of any action, proceeding
or investigation in respect of which indemnity may be sought pursuant to Section 6.1, such Indemnified Person shall promptly
notify the Company in writing, and the Company shall assume the defense thereof, and shall assume the payment of all fees and
expenses; provided, however , that the failure of any Indemnified Person so to notify the Company shall not relieve the Company
of its obligations hereunder except to the extent that the Company is actually prejudiced by such failure to notify. In any such
proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such counsel shall
be at the expense of such Indemnified Person unless: (i) the Company and the Indemnified Person shall have mutually agreed to
the retention of such counsel; (ii) the Company shall have failed promptly to assume the defense of such proceeding and to employ
counsel reasonably satisfactory to such Indemnified Person in such proceeding; or (iii) in the reasonable judgment of counsel
to such Indemnified Person, representation of both parties by the same counsel would be inappropriate due to actual or potential
differing interests between them in such proceeding; provided, that, in the case of the foregoing clauses (i) through (iii), the
Company shall not pay for more than one counsel for all Indemnified Persons. The Company shall not be liable for any settlement
of any proceeding effected without its written consent, which consent shall not be unreasonably withheld, delayed or conditioned.
Without the prior written consent of the Indemnified Person, which consent shall not be unreasonably withheld, delayed or conditioned,
the Company shall not effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person
is or could have been a party and indemnity could have been sought hereunder by such Indemnified Party, unless such settlement
includes an unconditional release of such Indemnified Person from all liability arising out of such proceeding.

 

    	 	22	 

    	 		 

    

 

Article
VII

MISCELLANEOUS

 

7.1
Termination. This Agreement may be terminated at any time prior to Closing upon notice by
the Company to the Investors of such termination.

 

7.2
Fees and Expenses. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the
fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party
incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer
Agent fees, stamp taxes and other taxes and duties levied in connection with the sale and issuance of the applicable Purchased
Shares.

 

7.3
Entire Agreement; Further Assurances. The Transaction Documents, together with the Exhibits, Annexes and Schedules thereto,
contain the entire understanding of the parties with respect to the subject matter hereof and supersede all prior agreements and
understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents,
exhibits and schedules. At or after the Closing, and without further consideration, the Company and the Investors will execute
and deliver to the Investors such further documents as may be reasonably requested in order to give practical effect to the intention
of the parties under the Transaction Documents.

 

7.4
Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall
be in writing and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication
is delivered via facsimile or email at the facsimile number or email address specified in this Section 7.4 prior to 6:30
p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication
is delivered via facsimile or email at the facsimile number or email address specified in this Section 7.4 on a day that
is not a Trading Day or later than 6:30 p.m. (New York City time) on any Trading Day, (c) the Trading Day following the date of
deposit with a nationally recognized overnight courier service, or (d) upon actual receipt by the party to whom such notice is
required to be given. The addresses, facsimile numbers and email addresses for such notices and communications are those set forth
on the signature pages hereof, or such other address or facsimile number as may be designated in writing hereafter, in the same
manner, by any such Person.

 

    	 	23	 

    	 		 

    

 

7.5
Amendments; Waivers. No provision of this Agreement may be waived or amended except in a
written instrument signed, in the case of an amendment, by the Company and the Investors holding or having the right to acquire
a majority of the Purchased Shares at the time of such amendment or, in the case of a waiver, by the party against whom enforcement
of any such waiver is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement
shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision,
condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair
the exercise of any such right.

 

7.6
Construction. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be
deemed to limit or affect any of the provisions hereof. The language used in this Agreement will be deemed to be the language
chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party.

 

7.7
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective
successors and permitted assigns. None of the parties may assign this Agreement or any of its respective rights or obligations
hereunder without the prior written consent of the other parties; provided, however this Agreement may be assigned by the Company
or any Investor to any corporation or association into which the Company or any Investor, as applicable, may be merged or converted
or with which it may be consolidated, or any corporation, association or other similar entity resulting from any merger, conversion
or consolidation to which the Company or the Investor shall be a party, as applicable, without the execution or filing of any
paper with any party hereto or any further act on the part of any of the parties to this Agreement except where an instrument
of transfer or assignment is required by law to effect such succession, anything herein to the contrary notwithstanding.

 

7.8
No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

7.9
Governing Law; Venue; Waiver of Jury Trial. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS
OF THE STATE OF NEW YORK without giving effect to any choice or conflict of law provision
or rule that would cause the application of the laws of any other jurisdiction. THE COMPANY AND INVESTORS HEREBY IRREVOCABLY
SUBMIT TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN FOR
THE ADJUDICATION OF ANY DISPUTE BROUGHT BY THE COMPANY OR ANY INVESTOR HEREUNDER, IN CONNECTION HEREWITH OR WITH ANY TRANSACTION
CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY
IRREVOCABLY WAIVE, AND AGREE NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING BROUGHT BY THE COMPANY OR ANY INVESTOR, ANY CLAIM
THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, OR THAT SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER.
EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION
OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO
SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD
AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO
SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. THE COMPANY AND INVESTORS HEREBY WAIVE ALL RIGHTS TO A TRIAL BY JURY.

 

    	 	24	 

    	 		 

    

 

7.10
Survival. Unless this Agreement is terminated under Section 7.1, the representations
and warranties, agreements and covenants contained herein shall survive indefinitely. Notwithstanding any termination of this
Agreement pursuant to Section 7.1, the provisions of Article VII shall survive indefinitely.

 

7.11
Execution. This Agreement may be executed in counterparts, all of which when taken together shall be considered one and
the same agreement. In the event that any signature is delivered by facsimile transmission or email attachment, such signature
shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same
force and effect as if such facsimile or email-attached signature page were an original thereof.

 

7.12
Severability. If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and
enforceability of the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and
the parties will attempt to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so
agreeing, shall incorporate such substitute provision in this Agreement.

 

7.13
Independent Nature of Investors’ Obligations and Rights. The obligations of each Investor under any Transaction Document
are several and not joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the
performance of the obligations of any other Investor under any Transaction Documents. The decision of each Investor to purchase
Common Shares pursuant to this Agreement has been made by such Investor independently of any other Investor and independently
of any information, materials, statements or opinions as to the business, affairs, operations, assets, properties, liabilities,
results of operations, condition (financial or otherwise) or prospects of the Company which may have been made or given by any
other Investor or by any agent or employee of any other Investor, and no Investor or any of its agents or employees shall have
any liability to any other Investor (or any other person) relating to or arising from any such information, materials, statements
or opinions. Nothing contained herein or in any Transaction Document, and no action taken by any Investor pursuant thereto, shall
be deemed to constitute the Investors as a partnership, an association, a joint venture or any other kind of entity, or create
a presumption that the Investors are in any way acting in concert or as a group with respect to such obligations or the transactions
contemplated by the Transaction Document. Each Investor acknowledges that no other Investor has acted as agent for such Investor
in connection with making its investment hereunder and that no other Investor will be acting as agent of such Investor in connection
with monitoring its investment hereunder. Each Investor shall be entitled to independently protect and enforce its rights, including
without limitation the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary
for any other Investor to be joined as an additional party in any Proceeding for such purpose.

 

    	 	25	 

    	 		 

    

 

7.14
Representations. Each Investor agrees that, except for the representations and warranties
contained in Section 3.1, the Company makes no other representations or warranties, and the Company hereby disclaims any
other representations or warranties made by itself or any of its directors, officers employees, investment bankers, financial
advisors, attorneys, accountants, agents and other representatives (collectively, “Representatives”), with
respect to the execution and delivery of this Agreement and the other Transaction Documents, notwithstanding the delivery or disclosure
to any other party or any other party’s Representatives of any document or other information with respect to any one or
more of the foregoing. Without limiting the generality of the foregoing, and notwithstanding any otherwise express representations
and warranties made by the Company in this Agreement, each of the Investors agrees that neither the Company nor any of its Subsidiaries
makes or has made any representation or warranty with respect to (i) any projections, forecasts, estimates, plans or budgets or
future revenues, expenses or expenditures, future results of operations (or any component thereof), future cash flows (or any
component thereof) or future financial condition (or any component thereof) of the Company or any of its Subsidiaries or the future
business, operations or affairs of the Company or any of its Subsidiaries heretofore or hereafter delivered to or made available
to it, or (ii) any other information, statements or documents heretofore or hereafter delivered to or made available to it with
respect to the Company or any of its Subsidiaries or the business, operations or affairs of the Company or any of its Subsidiaries,
except to the extent and as expressly covered by a representation and warranty made in this Agreement.

 

[SIGNATURE
PAGES FOLLOW]

 

    	 	26	 

    	 		 

    

 

IN
WITNESS WHEREOF, the parties hereto have executed or caused this Share Purchase Agreement to be duly executed by their respective
authorized signatories as of the date first indicated above.

 

	 	 	VBI
    Vaccines Inc. 
	 	 	 
	 	By:	
	 	Name:	Jeff
    Baxter 
	 	Title:	Chief
    Executive Officer
	 	 	 
	 	Address
                                         for Notice:

        222
        Third Street, Suite 2241

        Cambridge,
        MA 02142

	 	 	 
	 	Facsimile
    No.: 888.391.2579
	 	Email:
    JBaxter@vbivaccines.com 
	 	Attn:
    Jeff Baxter, CEO
	 	 
	 	With
    a copy to:
	 	 
	 	Mitchell
    Silberberg & Knupp LLP
	 	11377
                                         W. Olympic Blvd.

        Los
        Angeles, CA 90064

	 	 	 
	 	Facsimile
    No.: 310.312.3100
	 	Email:
    kxf@msk.com
	 	Attn:
    Kevin Friedmann, Esq.

 

 COMPANY
SIGNATURE PAGE TO SHARE PURCHASE AGREEMENT

 

    	 	 	 

    	 		 

    

 

Investor
Signature Page

 

IN
WITNESS WHEREOF, by its execution and delivery of this signature page, the undersigned Investor hereby joins in and agrees to
be bound by the terms and conditions of that certain Share Purchase Agreement, dated as of June 20, 2016 (the “Purchase
Agreement”), by and among VBI Vaccines Inc., a corporation organized under the laws of British Columbia, Canada and
the Investors (as defined therein), as to the number of Purchased Shares set forth below such Investor’s name on this signature
page, and authorizes this signature page to be attached to the Purchase Agreement or counterparts thereof.

 

 

	 	Name
    of Investor:
	 	 
	 	 	 
	 	By:
    	 
	 	Name:
    	 
	 	Title:	 
	 	 	 
	 	Investment Amount:
    	 
	 	 	 
	 	Address:	 
	 	 	 
	 	 	 
	 	 	 
	 	Telephone
    No.:	 
	 	 	 
	 	Facsimile
    No.:	 
	 	 	 
	 	Email
    Address:	 

 

Delivery
Instructions (if different than above):

 

	c/o:
    	 	 
	Address:
    	 	 
	 	 	 
	 	 	 
	Telephone
    No.: 	 	 
	Facsimile
    No. : 	 	 
	Other
    Special Instructions: 	 	 

 

Exhibits:

 

	 	A	Instruction
    Sheet for Investors
	 	A-1	Investor
    Questionnaire
	 	A-2	Investor
    Certificate
	 	A-3	Canadian
    Investor Certificate

 

    	 	 	 

    	 		 

    

 

Exhibit
A

 

INSTRUCTION
SHEET FOR INVESTOR

 

(to
be read in conjunction with the entire Share Purchase Agreement)

 

	A.	Complete
    the following items in the Share Purchase Agreement:
	 	 
	 	1.	Complete
    and execute the Investor Signature Page. The Share Purchase Agreement must be executed by an individual authorized to bind
    the Investor.
	 	 	 
	 	2.	Exhibit
    A-1 – Investor Questionnaire:
	 	 	 
	 	Provide
    the information requested by the Investor Questionnaire.
	 	 
	 	3	Exhibit
    A-2 - Investor Certificate:
	 	Provide
    the information requested by the Investor Certificate.
	 	 
	 	4.	Exhibit
    A-3- Canadian Investor Certificate
	 	Provide
    the information requested by the Canadian Investor Certificate.
	 	 
	 	5.	Return,
                                         via facsimile or email, the signed Share Purchase Agreement, including the properly completed
                                         Exhibits A-1, A-2 and A-3 to:

         

        Email:ggn@msk.com

	 	 	Facsimile:212.509.7239
	 	 	Telephone:917.546.7719
	 	 	Attn:Gabrielle
    Napolitano, Esq.
	 	 	 
	 	6.	After
    completing instruction number four (4) above, deliver the original signed Share Purchase Agreement, including the properly
    completed Exhibits A-1, A-2 and A-3 to:
	 	 	 
	 	 	Mitchell
                                         Silberberg & Knupp LLP

        12
        East 49th Street, 30th Floor

        New
        York, NY 10017

        Attn:
        Gabrielle Napolitano, Esq.

	 	 	 
	B.	Instructions
    regarding the wire transfer of funds for the purchase of the Purchased Shares will be sent by facsimile or email to the Investor
    by the Company at a later date.

 

    	 	 	 

    	 		 

    

 

Exhibit
A-1

 

VBI
VACCINES INC.

 

INVESTOR
QUESTIONNAIRE

 

	 	Please
    provide us with the following information:	 
	 	 	 
	1.	The
    exact name that the Purchased Shares are to be registered in (this is the name that will appear on any certificates or instruments
    evidencing the Purchased Shares). You may use a nominee name if appropriate:	 
	 	 	 
	2.	The
    relationship between the Investor and the registered holder listed in response to item 1 above (if other than the Investor):	 
	 	 	 
	3.	The
    mailing address, telephone and fax number and email address of the registered holder listed in response to item 1 above:	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	4.	The
    Tax Identification Number of the Registered Holder listed in response to item 1 above:	 

 

    	 	 A-1	 

    	 		 

    

 

Exhibit
A-2

 

VBI
VACCINES INC.

 

CERTIFICATE
FOR CORPORATE, PARTNERSHIP, LIMITED LIABILITY COMPANY,

TRUST, FOUNDATION AND JOINT INVESTORS

 

If
the Investor is a corporation, partnership, limited liability company, trust, pension plan, foundation, joint Investor (other
than a married couple) or other entity, an authorized officer, partner, or trustee must complete, date and sign this Certificate.

 

CERTIFICATE

 

The
undersigned certifies that the representations and responses below are true and accurate:

 

(a)       The
Investor has been duly formed, is validly existing and has full power and authority to invest in the Company. The person signing
on behalf of the undersigned has the authority to execute and deliver the Share Purchase Agreement on behalf of the Investor and
to take other actions with respect thereto.

 

(b)       Indicate
the form of entity of the undersigned:

 

____Limited
Partnership

 

____General
Partnership

 

____Limited
Liability Company

 

____Corporation

 

____Revocable
Trust (identify each grantor and indicate under what circumstances the trust is revocable by the grantor):

 

 

 

(Continue
on a separate piece of paper, if necessary.)

 

____Other
type of Trust (indicate type of trust and, for trusts other than pension trusts, name the grantors and beneficiaries):

 

 

 

(Continue
on a separate piece of paper, if necessary.)

 

____Other
form of organization (indicate form of organization (                                                                  

                                                                                                                                                                                                      ).

 

(c)Indicate
the approximate date the undersigned entity was formed:                  .

 

    	 	 A-2	 

    	 		 

    

 

(d)       In
order for the Company to offer and sell the Purchased Shares in conformance with applicable securities laws, the following information
must be obtained regarding your investor status. Please initial each category applicable to you as an Investor in the Company.

 

	 	___	1.	A
    bank as defined in Section 3(a)(2) of the Securities Act, or any savings and loan association or other institution as defined
    in Section 3(a)(5)(A) of the Securities Act whether acting in its individual or fiduciary capacity;
	 	 	 	 
	 	___	2.	A
    broker or dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934;
	 	 	 	 
	 	___	3.	An
    insurance company as defined in Section 2(13) of the Securities Act;
	 	 	 	 
	 	___	4.	An
    investment company registered under the Investment Company Act of 1940 or a business development company as defined in Section
    2(a)(48) of that Act;
	 	 	 	 
	 	___	5.	A
    Small Business Investment Company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the Small
    Business Investment Act of 1958;
	 	 	 	 
	 	___	6.	A
    plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its
    political subdivisions, for the benefit of its employees, if such plan has total assets in excess of $5,000,000;
	 	 	 	 
	 	___	7.	An
    employee benefit plan within the meaning of the Employee Retirement Income Security Act of 1974, if the investment decision
    is made by a plan fiduciary, as defined in Section 3(21) of such Act, which is either a bank, savings and loan association,
    insurance company, or registered investment advisor, or if the employee benefit plan has total assets in excess of $5,000,000
    or, if a self-directed plan, with investment decisions made solely by persons that are accredited investors;
	 	 	 	 
	 	___	8.	A
    private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940;
	 	 	 	 
	 	___	9.	Any
    partnership or corporation or any organization described in Section 501(c)(3) of the Internal Revenue Code or similar business
    trust, not formed for the specific purpose of acquiring the Purchased Shares, with total assets in excess of $5,000,000;
	 	 	 	 
	 	___	10.	A
    trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the Purchased Shares, whose
    purchase is directed by a sophisticated person as described in Rule 506(b)(2)(ii) of the Exchange Act;
	 	 	 	 
	 	___	11.	A
    “qualified institutional buyer” as defined by Rule 144A under the Securities Act;
	 	 	 	 
	 	___	12.	An
                                         entity in which all of the equity owners qualify under any of the above subparagraphs
                                         (or each such equity owner is a natural person who either (i) has an individual net worth,
                                         or joint net worth with such person’s spouse, in excess of $1,000,000 (exclusive
                                         of such person’s primary residence)[1]
                                         or (ii) had an individual income in excess of $200,000 in each of the two most recent
                                         years or joint income with that person’s spouse in excess of $300,000 in each of
                                         those years and has a reasonable expectation of reaching the same income level in the
                                         current year). If the undersigned belongs to this investor category only, list the equity
                                         owners of the undersigned, and, with respect to each equity owner that is not a natural
                                         person, the investor category which each such equity owner satisfies:

        ___________________________________________________________________________

        

        (Continue on a separate piece of paper, if necessary.)

 

    	 	 A-2	 

    	 		 

    

 

Please
set forth in the space provided below the (i) states, if any, in the U.S. in which you maintained your principal office during
the past two years and the dates during which you maintained your office in each state, (ii) state(s), if any, in which you are
incorporated or otherwise organized and (iii) state(s), if any, in which you pay income taxes.

 

 

 

 

 

 

 

 

	Dated:__________________________,
    2016	 
	 	 
	 	 
	Print
    Name of Investor	 
	 	 
	 	 
	Name:	 
	Title:	 
	(Signature
    and title of authorized officer, partner or trustee)	 

 

 

	1	For purposes of calculation of net
    worth in paragraph (12) above, (i) the undersigned’s primary residence shall not be included as an asset; (ii) indebtedness
    secured by the undersigned’s primary residence, up to the estimated fair market value of such primary residence as of
    the date hereof, shall not be included as a liability (except that if the amount of such indebtedness outstanding as of the
    date hereof exceeds the amount outstanding as of 60 days before the date hereof, other than as a result of the acquisition
    of such primary residence, the amount of such excess shall be included as a liability) and (ii i) indebtedness that is secured
    by the undersigned’s primary residence in excess of the estimated fair market value of such primary residence as of
    the date hereof, shall be included as a liability. 

 

    	 	 A-2	 

    	 		 

    

 

Exhibit
A-3

 

CANADIAN
INVESTOR CERTIFICATE

 

TO:VBI
Vaccines Inc. (the “Issuer”)

 

Reference
is made to the share purchase agreement between the Issuer and the undersigned (referred to herein as the “Purchaser”)
dated as of the date hereof (the “Share Purchase Agreement”). Upon execution of this Canadian Investor Certificate
by the Purchaser, this Canadian Investor Certificate shall be incorporated into and form a part of the Share Purchase Agreement.
Terms not otherwise defined herein have the meanings attributed to them in the Share Purchase Agreement and in National Instrument
45-106 Prospectus Exemptions (“NI 45-106”)[2]. All monetary references are in Canadian
dollars.

 

In
connection with the purchase of the Purchased Shares by the Purchaser, the Purchaser represents, warrants and covenants (on its
own behalf or, if applicable, on behalf of those for whom the Purchaser is contracting under the Share Purchase Agreement) and
certifies to the Issuer and acknowledges that the Issuer is relying thereon that:

 

Prospectus
Exemption

 

	A

         

        [  ]
	the
                                         clause checked below applies:

         

        (i)       the
        Purchaser is purchasing the Purchased Shares as principal; or

         

	[  ]	(ii)      the
                                         Purchaser is deemed to be purchasing as principal under Applicable Securities Laws, in
                                         accordance with the following statutory provision:

         

        [State
        particulars, including statutory provision and basis on which Purchaser is deemed to be purchasing as principal]

         

	 	 
	 	 
	B	one
                                         of the following clauses (1), (2) or (3) applies (Please check the applicable exemptions
                                         upon which the Purchaser is relying):

                                                                                 

	[  ]	(1)	the
                                         Purchased Shares have an acquisition cost to the Purchaser of not less than $150,000
                                         paid in cash, and the Purchaser is not an individual or an entity created or used solely
                                         to purchase or hold securities in reliance upon the exemption contained in section 2.10
                                         of NI 45-106;

                                                                                 

	 	(2)	the
                                         Purchaser is an “Accredited Investor” as such term is defined in NI
                                         45-106, and as at the Closing Date, the Purchaser falls within the following categories:

                                                                                 

	[  ]	 	(a)	a
    Canadian financial institution, or a Schedule III bank,
	 	 	 	 	 

 

	2	Terms used herein
    that are defined in National Instrument 14-101 (“NI 14 -101”) as adopted by the securities regulatory authority
    in the jurisdiction of the Purchaser have the meaning given to them in NI 14 -101 and terms used herein that are defined in
    the securities legislation of the jurisdiction of the Purchaser have the meaning given to them in that legislation. Reference
    should be made to NI 45-106 itself for its complete text, including other definitions, and to the Companion Policy to NI 45
    -106 for matters of interpretation and application.

 

    	 	 A-3	 

    	 		 

    

 

	[  ]	(b)	the
    Business Development Bank of Canada incorporated under the Business Development Bank of Canada Act (Canada),
	 	 	 
	 [  ]	(c)	a
    subsidiary of any person referred to in paragraphs (a) or (b), if the person owns all of the voting securities of the subsidiary,
    except the voting securities required by law to be owned by directors of that subsidiary,
	 	 	 
	[  ]	(d)	a
    person registered under the securities legislation of a jurisdiction of Canada as an adviser or dealer,
	 	 	 
	[  ]	(e)	an
    individual registered under the securities legislation of a jurisdiction of Canada as a representative of a person referred
    to in paragraph (d),
	 	 	 
	[  ]	(e.1)	an
    individual formerly registered under the securities legislation of a jurisdiction of Canada, other than an individual formerly
    registered solely as a representative of a limited market dealer under one or both of the Securities Act (Ontario)
    or the Securities Act (Newfoundland and Labrador),
	 	 	 
	[  ]	(f)	the
    Government of Canada or a jurisdiction of Canada, or any crown corporation, agency or wholly owned entity of the Government
    of Canada or a jurisdiction of Canada,
	 	 	 
	[  ]	(g)	a
    municipality, public board or commission in Canada and a metropolitan community, school board, the Comité de gestion
    de la taxe scolaire de l’île de Montréal or an intermunicipal management board in Québec;
	 	 	 
	[  ]	(h)	any
    national, federal, state, provincial, territorial or municipal government of or in any foreign jurisdiction, or any agency
    of that government,
	 	 	 
	[  ]	(i)(i)	a
    pension fund that is regulated by either the Office of the Superintendent of Financial Institutions (Canada) or a pension
    commission or similar regulatory authority of a jurisdiction of Canada,
	 	 	 
	[  ]

         

         
	(j)	an
                                         individual who, either alone or with a spouse, beneficially owns financial assets having
                                         an aggregate realizable value that before taxes, but net of any related liabilities (“Net
                                         Financial Assets”), exceeds $1,000,000,

         

        Note:
        if you fall within this category, please complete the following steps:

         

        Step
        1: Complete the Risk Acknowledgement Form at Appendix I to this Schedule A

         

        Step
        2: Complete the following tables with information for individual alone or with spouse 

 

	 	I,
    alone, own the following categories of Net Financial Assets:	 	I,
    together with my spouse, own the following categories of Net Financial Assets:
	 	 	 	 	 	 
	 	Net
    Financial Assets 	 	 	Net
    Financial Assets	 
	 	 	 	 	 	 
	 	Cash	[  ]	 	Cash	[  ]
	 	Securities	[  ]	 	Securities	[  ]
	 	Contract
    of insurance or deposit	[  ]	 	Contract
    of insurance or deposit	[  ]
	 	Other	[  ]
    	 	Other	[  ]

 

	 	such
    Net Financial Assets having the following aggregate value:	 	 	such
    Net Financial Assets having the following aggregate value:
	 	 	 	 	 	 
	 	Aggregate
    Value of Net Financial Assets	 	 	Aggregate
    Value of Net Financial Assets
	 	Under
    $500,000	[  ]	 	Under
    $500,000	[  ]
	 	$500,000-$900,000	[  ]	 	$500,000-$900,000	[  ]
	 	$900,000-$1,000,000	[  ]	 	$900,000-$1,000,000	[  ]
	 	Over
    $1,000,000	[  ]	 	Over
    $1,000,000	[  ]

 

    	 	 A-3	 

    	 		 

    

 

	[  ]	(j.1)	an
                                         individual who beneficially owns financial assets having an aggregate realizable value
                                         that, before taxes but net of any related liabilities, exceeds $5,000,000,

         

        Note:
        if you fall within this category, please complete the following tables with information for individual alone:

 

	 	I,
    alone, own the following categories of Net Financial Assets:	 
	 	 	 	 
	 	Net
    Financial Assets 	 	 
	 	Cash	[  ]	 
	 	Securities	[  ]	 
	 	Contract
    of insurance or deposit	[  ]	 
	 	Other	[  ]
     	 
	 	Such
    Net Financial Assets having the following aggregate value:	 
	 	 	 	 
	 	Aggregate
    Net Financial Assets	 	 
	 	Under
    $1,000,000	[  ]	 
	 	$1,000,000-$3,000,000	[  ]	 
	 	$3,000,000-$5,000,000	[  ]	 
	 	Over
    $5,000,000 	[  ]	 

 

	[  ]	(k)	an
                                         individual whose net income before taxes (“Net Income”) exceeded $200,000
                                         in each of the 2 most recent calendar years or whose net income before taxes combined
                                         with that of a spouse exceeded $300,000 in each of the 2 most recent calendar years and
                                         who, in either case, reasonably expects to exceed that net income level in the current
                                         calendar year,

         

        Note:
        if you fall within this category, please complete the following steps:

         

        Step
        1: Complete the Risk Acknowledgement Form at Appendix I to this Schedule A

         

        Step
        2: Please provide the following information regarding actual or net income (check one category for each year): 

 

	 	Individual
    	Joint
    Income With Spouse5	 
	 	 	 	 	 	 	 	 
	 	Net
    Income	2014	2015	Net
    Income	2014	2015	 
	 	Under
    $100,000	[  ]	[  ]	Under
    $150,000	[  ]	[  ]	 
	 	$100,000-$200,000	[  ]	[  ]	$150,000-$300,000	[  ]	[  ]	 
	 	$200,000-$500,000	[  ]	[  ]	$300,000-$500,000	[  ]	[  ]	 
	 	Above
    $500,000	[  ]	[  ]	Above
    $500,000	[  ]	[  ]	 

 

	 	I
    expect that my individual Net Income in 2015 will meet or exceed the above noted income levels. __Yes __No	 	I
    expect that my joint Net Income with my spouse in 2015 will meet or exceed the above noted income levels. __Yes __No

 

    	 	 A-3	 

    	 		 

    

 

	[  ]	(l)	an
                                         individual who, either alone or with a spouse[3], has net assets of at least
                                         $5,000,000,

         

        Note:
        if you fall within this category, please complete the following steps:

         

        Step
        1: Complete the Risk Acknowledgement Form at Appendix I to this Schedule A.

         

        Step
        2: Complete the following tables with information for individual alone or with Spouse

 

	 	I,
    alone, own the following categories of Net Assets:	 	I,
    together with my spouse, own the following categories of Net Assets:
	 	 	 	 	 	 
	 	Net
    Assets 	 	 	Net
    Assets 	 
	 	Cash	[  ]	 	Cash	[
     ]
	 	Securities	[
     ]	 	 Securities	[
     ]
	 	Contract
    of insurance or deposit	[
     ]	 	Contract
    of insurance or deposit	[
     ]
	 	Real
    Estate	[
     ]	 	Real
    Estate	[
     ]
	 	Other	[
     ]	 	Other	[
     ]

 

	 	such
    Net Assets having the following aggregate value:	 	such
    Net Assets having the following aggregate value:
	 	 	 	 	 	 
	 	Aggregate
    Value of Net Assets	 	 	Aggregate
    Value of Net Assets	 
	 	 	 	 	 	 
	 	Under
    $1,000,000	[
     ]	 	Under
    $1,000,000	[
     ]
	 	$1,000,000-$3,000,000	[
     ]	 	$1,000,000-$3,000,000	[
     ]
	 	$3,000,000-$5,000,000	[
     ]	 	$3,000,000-$5,000,000	[
     ]
	 	Over
    $5,000,000	[
     ]	 	Over
    $5,000,000	[
     ]

 

	[  ]	(m)	a
                                         person, other than an individual or investment fund, that has net assets[4]
                                         of at least $5,000,000 as shown on its most recently prepared financial statements, and
                                         such person has not been created or used solely to purchase or hold securities as an
                                         accredited investor,

         

        Note:
        if you fall within this category, please provide the most recently prepared financial statements confirming this category. 

         

	[  ]	(n)	an
                                         investment fund that distributes or has distributed its securities only to

                                                                            

	 	 	(i)       a
                                         person that is or was an Accredited Investor at the time of the distribution,

         

        Note:
        if you fall within this category, please complete the following:

         

        I,
        ,
        am an authorized signatory of the Purchaser and confirm that the all persons who have been distributed securities of the
        investment are Accredited Investors and the Purchaser has done the necessary investigations to verify that fact.

 

 

	3	For pur poses of this certificate,
    the term “spouse” means an individual who (i) is married to another individual and is not living separate and
    apart within the meaning of the Divorce Act (Canada) from the other individual, (ii) is living with another individual in
    a marriage-like relationship, including a marriage-like relationship between individuals of the same gender, or (iii) in Alberta,
    is an individual referred to in paragraph (i) or (ii) above, or is an adult interdependent partner within the meaning of the
    Adult Interdependent Relationships Act (Alberta).
	4	For the purposes of this certificate,
    “net assets” means the value of the total assets of the purchaser less the value of the total liabilities.

 

    	 	 A-3	 

    	 		 

    

 

	 	 	(ii)	a
    person that acquires or acquired securities in the circumstances referred to in sections 2.10 of NI 45-106 [Minimum
    amount investment], or 2.19 of NI 45-106 [Additional investment in investment funds], or
	 	 	 	 
	 	 	(iii)	a
    person described in paragraph (i) or (ii) that acquires or acquired securities under section 2.18 of NI 45-106 [Investment
    fund reinvestment],

 

	[  ]	(o)	an investment fund
    that distributes or has distributed securities under a prospectus in a jurisdiction of Canada for which the regulator or,
    in Québec, the securities regulatory authority, has issued a receipt,
	[  ]	(p)	a trust company
    or trust corporation registered or authorized to carry on business under the Trust and Loan Companies Act (Canada)
    or under comparable legislation in a jurisdiction of Canada or a foreign jurisdiction, acting on behalf of a fully managed
    account managed by the trust company or trust corporation, as the case may be,
	[  ]	(q)	a person acting
    on behalf of a fully managed account[1] managed by that person, if that person is registered or authorized to carry
    on business as an adviser or the equivalent under the securities legislation of a jurisdiction of Canada or a foreign jurisdiction,
	[  ]	(r)	a registered charity
    under the Income Tax Act (Canada) that, in regard to the trade, has obtained advice from an eligibility adviser or
    an adviser registered under the securities legislation of the jurisdiction of the registered charity to give advice on the
    securities being traded[2],
	[  ]	(s)	an entity organized
    in a foreign jurisdiction that is analogous to any of the entities referred to in paragraphs (a) to (d) or paragraph (i) in
    form and function,
	[  ]	(t)	a
        person in respect of which all of the owners of interests, direct, indirect or beneficial, except the voting securities
        required by law to be owned by directors, are persons that are Accredited Investors,

         

        Note:
        if you fall within this category, please complete the following:

         

        I,
        ___________________________________, am an authorized signatory of the Purchaser and confirm that all owners of interest
        of the Purchaser are Accredited Investors and the Purchaser has done the necessary investigations to verify that fact.

	[  ]	(u)	an investment fund
    that is advised by a person registered as, an adviser or, a person that is exempt from registration as an adviser,
	[  ]

         

        [  ]
	(v)       

         

        (w)       
	a
        person that is recognized or designated by the securities regulatory authority or, except in Ontario and Québec,
        the regulator as an Accredited Investor; or

         

        a
        trust established by an accredited investor for the benefit of the accredited investor’s family members of which
        a majority of the trustees are accredited investors and all of the beneficiaries are the accredited investor’s spouse,
        a former spouse of the accredited investor or a parent, grandparent, brother, sister, child or grandchild of that accredited
        investor, of that accredited investor’s spouse or of that accredited investor’s former spouse;

         

	 	 	the Purchaser is
    purchasing pursuant to an exemption from prospectus requirements available to it under NI 45-106 not set out in (1)
    or (2) above, the particulars of which are set out below:
	 	 	 
	 	 	                                                                      
	 	 	                                                                      
	 	 	                                                                      

 

	 	By:	 
	 	 	Signature

 

	 	 
	 	Print
        name of Signatory 

        (if
        different from Purchaser)

	 	 
	 	 
	 	Title

 

 

	5	A
                                         “fully managed account” means an account of a client for which a person makes
                                         the investment decisions if that person has full discretion to trade in securities for
                                         the account without requiring the client’s express consent to a transaction.
	6	For
                                         the purposes of this certificate, an “eligibility adviser” means (a) a person
                                         that is registered as an investment dealer and authorized to give advice with respect
                                         to the Purchased Shares; and (b) in Saskatchewan or Manitoba, also means a lawyer who
                                         is a practising member in good standing with a law society of a jurisdiction of Canada
                                         or a public accountant who is a member in good standing of an institute or association
                                         of chartered accountants, certified general accountants or management accountants in
                                         a jurisdiction of Canada, provided that the lawyer or public accountant (a) does not
                                         have a professional, business or personal relationship with the Issuer, or any of its
                                         directors, executive officers, founders or control persons, and (b) has not acted for
                                         or been retained personally or otherwise as an employee, executive officer, director,
                                         associate or partner of a person or company that has acted for or been retained by the
                                         Issuer or any of its directors, executive officers, founders or control persons within
                                         the previous 12 months.

 

    	 	 A-3	 

    	 		 

    

 

APPENDIX
1 TO EXHIBIT “A-3”

 

INDIVIDUAL
ACCREDITED INVESTOR RISK ACKNOWLEDGMENT FORM

 

Form
45-106F9

 

Risk
Acknowledgement Form for Accredited Investors who are Individuals

 

	WARNING!

                            This
                            investment is risky. Don’t invest unless you can afford to lose all the

                            money
                            you pay for this investment

 

	SECTION
    1 TO BE COMPLETED BY THE ISSUER OR SELLING SECURITY HOLDER
	1.
    About your investment
	Type
    of securities: Common Shares 	Issuer:
    VBI Vaccines Inc. (the “Company”)
	Purchased
    from: the Company
	SECTIONS
    2 TO 4 TO BE COMPLETED BY THE PURCHASER
	2.
    Risk acknowledgement
	This
    investment is risky. Initial that you understand that:	Your
    initials
	Risk
    of loss – You could lose your entire investment of $____________________ . [Instruction: Insert the total dollar
    amount of the investment.]	 
	Liquidity
    risk – You may not be able to sell your investment quickly – or at all.	 
	Lack
    of information – You may receive little or no information about your investment.	 
	Lack
    of advice – You will not receive advice from the salesperson about whether this investment is suitable for you unless
    the salesperson is registered. The salesperson is the person who meets with, or provides information to, you about making
    this investment. To check whether the salesperson is registered, go to www.aretheyregistered.ca.	 
	3.
    Accredited investor status
	You
    must meet at least one of the following criteria to be able to make this investment. Initial the statement that applies
    to you. (You may initial more than one statement.) The person identified in section 6 is responsible for ensuring that you
    meet the definition of accredited investor. That person, or the salesperson identified in section 5, can help you if you have
    questions about whether you meet these criteria.	Your
    initials
	•
    Your net income before taxes was more than $200,000 in each of the 2 most recent calendar years, and you expect it to be more
    than $200,000 in the current calendar year. (You can find your net income before taxes on your personal income tax return.)	 
	•
    Your net income before taxes combined with your spouse’s was more than $300,000 in each of the 2 most recent calendar
    years, and you expect your combined net income before taxes to be more than $300,000 in the current calendar year.	 
	•
    Either alone or with your spouse, you own more than $1 million in cash and securities, after subtracting any debt related
    to the cash and securities.	 
	•
    Either alone or with your spouse, you have net assets worth more than $5 million. (Your net assets are your total assets (including
    real estate) minus your total debt.)	 
	4.
    Your name and signature
	By
    signing this form, you confirm that you have read this form and you understand the risks of making this investment as identified
    in this form.
	First
    and last name (please print):
	Signature:	Date:
	SECTION
    5 TO BE COMPLETED BY THE SALESPERSON
	5.
    Salesperson information
	[Instruction:
    The salesperson is the person who meets with, or provides information to, the purchaser with respect to making this investment.
    That could include a representative of the issuer, a registrant or a person who is exempt from the registration requirement.]
	First
    and last name of salesperson (please print):
	Telephone:	Email:
	Name
    of firm (if registered):
	SECTION
    6 TO BE COMPLETED BY THE ISSUER OR SELLING SECURITY HOLDER
	6.
    For more information about this investment
	VBI
                                         Vaccines Inc. – 222 Third Street, Suite 2241, Cambridge, Massachusetts 02142

         

        Attention:
        Jeff Baxter, Tel: (617) 830-3031, Email: JBaxter@vbivaccines.com, www.vbivaccines.com

         

        For
        more information about prospectus exemptions, contact your local securities regulator. You can find contact information
        at www.securities-administrators.ca.

	 	 	 	 	 

 Form
instructions:

 

1.       The
information in sections 1, 5 and 6 must be completed before the purchaser completes and signs the form.

 

2.       The
purchaser must sign this form. Each of the purchaser and the issuer or selling security holder must receive a copy of this form
signed by the purchaser. The issuer or selling security holder is required to keep a copy of this form for 8 years after the distribution.

 

    	 	 A-3	 

    	 		 

    

 

EXHIBIT
B

 

Company
Account Wire Instructions

  

VBI
Vaccines Inc.

222
Third Street, Suite 2241

Cambridge,
MA 02142

 

Beneficiary
account number: 0004 4660-595

 

Beneficiary
Bank: Bank of Montreal

 

Branch
Address: 595 Burrard Street, Vancouver, B.C. V7X1L7

 

BMO’s
bank number: 00100040

 

BMO
SWIFT BIC Code: BOFMCAM2

 

USD
correspondent bank information

 

Pay
through: Wells Fargo Bank (FKA Wachovia)

S.W.I.F.T BIC Code: PNBPUS3NNYC

AND - Fedwire ABA: 026005092

OR – CHIPS participant: 0509

 

    	 	Exhibit B

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}]]